NewAmsterdam Pharma Company NV has published a document detailing the safety and efficacy of obicetrapib in patients at high cardiovascular risk. The document includes information on a study involving 2530 adult participants with heterozygous familial hypercholesterolemia and/or atherosclerotic cardiovascular disease. Key findings include the placebo-adjusted reduction in LDL-C with obicetrapib, which was 32.6% at day 84 and 24.0% at day 365. The full document can be accessed through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。